CLAIMS:

1. A Tandem Fc Bispecific Antibody ("TFcBA") comprising a large chain and a Fab light chain, each chain having a C-terminus and an N-terminus, the TFcBA comprising a Fab moiety comprising a first binding site comprising the Fab light chain and a Fab heavy chain, wherein the Fab heavy chain is at the N-terminus of the large chain, wherein the Fab moiety specifically binds to cMet, and wherein the TFcBA further comprises a single chain Fv (scFv) moiety at the C-terminus of the large chain, wherein the scFv moiety comprises a second binding site that specifically binds to EpCAM, wherein:

(a) the large chain comprises the amino acid sequence of SEQ ID NO: 410; and

(b) the Fab light chain comprises the amino acid sequence of SEQ ID NO: 400.

2. A pharmaceutical formulation comprising the TFcBA of claim 1 and a pharmaceutical carrier.

3. The pharmaceutical formulation of claim 2, wherein the formulation is a sterile formulation suitable for one or more of the following: injection, intravenous injection, and infusion.